RT Journal Article
SR Electronic
T1 Seroreversion to <em>Chlamydia trachomatis</em> Pgp3 antigen among children in a hyperendemic region of Amhara, Ethiopia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.02.04.23285360
DO 10.1101/2023.02.04.23285360
A1 Tedijanto, Christine
A1 Aragie, Solomon
A1 Gwyn, Sarah
A1 Wittberg, Dionna M.
A1 Zeru, Taye
A1 Tadesse, Zerihun
A1 Chernet, Ambahun
A1 Thompson, Isabel J.B.
A1 Nash, Scott D.
A1 Lietman, Thomas M.
A1 Martin, Diana L.
A1 Keenan, Jeremy D.
A1 Arnold, Benjamin F.
YR 2023
UL http://medrxiv.org/content/early/2023/12/21/2023.02.04.23285360.abstract
AB Monitoring trachoma transmission with antibody data requires characterization of decay in IgG to Chlamydia trachomatis antigens. In a three-year longitudinal cohort in a high transmission setting, we estimated a median IgG half-life of 3 years and a seroreversion rate of 2.5 (95% CI: 1.6, 3.5) per 100 person-years.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the National Institute of Allergy and Infectious Disease [R01-AI158884 to B.F.A.] and the National Eye Institute [UG1-EY023939 to J.D.K.].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research was approved by a human subjects review board at the University of California, San Francisco. Each participant or guardian provided verbal consent before any study activity, with separate consent required for census, examinations and intervention at each study visit.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData and replication files are available: https://osf.io/xquyd/ https://osf.io/xquyd/